VTVT - vTv Therapeutics posts data from mid-stage TTP399 diabetes study

vTv Therapeutics ([[VTVT]] -8.4%) announces that the results from the JDRF-supported SimpliciT-1 Study were published in the American Diabetes Association’s Diabetes Care journal, where treatment with 800mg of TTP399 showed statistically significant reductions in HbA1c blood sugar level.The Phase 2 study was conducted in two parts under a treat-to-target protocol to evaluate the safety and efficacy of TTP399 in type 1 diabetes patients over 12 weeks of daily dosing following a multi-week insulin optimization and placebo run-in period.The data suggests the potential of TTP399 to lower HbA1c and reduce hypoglycemia without increasing the risk of ketosis and should be further evaluated as an adjunctive therapy for the treatment of type 1 diabetes.vTv expects to initiate its first pivotal study of TTP399 later this year.

For further details see:

vTv Therapeutics posts data from mid-stage TTP399 diabetes study